Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharmaceuticals, Inc. - Common Stock (NQ:INO)

1.730 -0.030 (-1.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inovio Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript
INO earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For March 18, 2025
Via Benzinga
What's Going On With Inovio Pharmaceuticals (INO) Stock?
Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. 
Via Benzinga
Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing
Inovio Pharmaceuticals shares are trading higher by 20.7% Tuesday afternoon. Vaccine stocks are rising amid growing concerns about respiratory illnesses. 
Via Benzinga
Top 3 Health Care Stocks That Could Blast Off This Month
Via Benzinga
The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals
Via Benzinga
A Preview Of Inovio Pharmaceuticals's Earnings
Via Benzinga
The Analyst Verdict: Inovio Pharmaceuticals In The Eyes Of 4 Experts
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
Via Benzinga
Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast
Via Benzinga
Exposures Fossil Fuels
US Stocks Mixed; Broadcom Shares Surge On Upbeat Earnings
Via Benzinga
Why Inovio Pharmaceuticals (INO) Stock Is Down 40%
Inovio Pharmaceuticals shares are trading lower by 38% during Friday's session. The company priced a public offering of 10 million shares of common stock and accompanying warrants. 
Via Benzinga
US Stocks Likely To Open Higher, Investors Eye Fed Policy Meet Next Week: Broadcom, RH, Costco In Focus
U.S. stock futures advanced on Friday in premarket after declining on Thursday. The futures of all four major indices were trading higher. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
RH, Broadcom And 3 Stocks To Watch Heading Into Friday
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Exposures Product Safety
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript
INO earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript
INO earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
INO Stock Earnings: Inovio Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
INO stock results show that Inovio Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Earnings Scheduled For November 14, 2024
Via Benzinga
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
Better Buy: Inovio Pharmaceuticals vs. Novavax
Both biotechs have been struggling for a while, but there might be some hope for them. 
Via The Motley Fool
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst
Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non-surgical RRP... 
Via Benzinga
Exposures Product Safety
Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript
INO earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
INO Stock Earnings: Inovio Pharmaceuticals Misses EPS for Q1 2024
INO stock results show that Inovio Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
Can the biotech succeed after a string of failures? 
Via The Motley Fool
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.